Related Experiment Videos
[Clinical evaluation of cefotetan in pediatrics]
The Japanese Journal of Antibiotics
|June 1, 1983
Insights
Cefotetan effectively treated acute bacterial infections in fifteen children, showing excellent or satisfactory results in eleven patients. No adverse reactions were observed during the treatment period.
Area of Science:
- Pediatric infectious diseases
- Bacteriology
- Pharmacology
Context:
- Acute bacterial infections pose a significant health challenge in pediatric populations.
- Antibiotic resistance necessitates the evaluation of effective treatment options.
- Cefotetan is a cephalosporin antibiotic with broad-spectrum activity.
Purpose:
- To evaluate the efficacy and safety of cefotetan in treating acute bacterial infections in children.
- To assess treatment outcomes and identify any adverse reactions associated with cefotetan therapy.
Summary:
- Fifteen pediatric patients with various acute bacterial infections (pneumonia, pharyngitis, cervical lymphadenitis, peritonitis, gastroenteritis, UTI) received cefotetan.
- The antibiotic demonstrated high efficacy, with excellent results in 2 patients and satisfactory results in 9.
- No adverse reactions were reported in any of the treated patients during or after the administration of cefotetan at 30-60 mg/kg/day for 4-11 days.
Impact:
- Cefotetan presents a safe and effective therapeutic option for pediatric bacterial infections.
- The findings support the use of cefotetan in clinical practice for managing pediatric infectious diseases.
- Further research may explore cefotetan's role in specific resistant bacterial infections.
Abstract:
Fifteen children with acute bacterial infections, including pneumonia (8), pharyngitis (2), cervical lymphadenitis (1), perforative peritonitis (1), gastroenteritis (1) and urinary tract infection (2), were treated with cefotetan. This drug was effective to all of the patients. In 2 patients the result was excellent and in 9 it was satisfactory. No adverse reactions were observed in the above cases and 2 other patients, during and after the dosage of 30-60 mg/kg/day for 4-11 days.